A MONOCLONAL ANTI-DC1 ANTIBODY SELECTIVELY INHIBITS THE GENERATION OF EFFECTOR T CELLS MEDIATING SPECIFIC CYTOLYTIC ACTIVITY*

By G. CORTE, A. MORETTA, M. E. COSULICH, D. RAMARLI, AND A. BARGELLESI

From the Istituto di Chimica Biologica, Università di Genova, Italy; and the Ludwig Institute for Cancer Research, Epalinges, Switzerland

The human Ia region of the major histocompatibility complex (MHC) is composed of a cluster of genes in strong linkage disequilibrium with each other, coding for molecules similar in structure expressed on the surface of B lymphocytes, macrophages, and T cells, especially upon activation. Since the first locus, DR, was recognized in the VII Histocompatibility Workshop, direct evidence has been obtained for at least two more loci, DC and BR, possessing genetic markers defined by specific alloantisera (1). The products of the DR locus are the predominant species of Ia molecules, accounting for at least 60% of the Ia pool (2). There is no doubt that DR molecules play a role in the mixed lymphocyte reaction (MLR) (3). Recent studies have shown that proliferation of T cells can be strongly inhibited by pretreatment of either the responder T cells or the stimulating cells with monoclonal antibodies specific for products of the DR locus (4, 5).

The products of the DC locus constitute a smaller fraction of Ia molecules (2). They have been shown both by microfingerprinting (6) and by two-dimensional gel analysis (7) to differ from DR molecules in both subunits. These substantial structural differences suggested the possibility that DC molecules could have functional properties distinct from those of DR molecules. The availability of a monoclonal antibody (MAb) specifically directed against an allelic DC determinant, DC1 (nomenclature equivalent MB1, MT1, LB12), a DC determinant in strong linkage disequilibrium with DR1,2 and w6 (8), makes it possible to test this hypothesis.

In this study we have investigated the effect of the anti DC1 MAb on MLR and other in vitro systems. We show here that, unlike anti-DR antibodies, anti-DC1 has no effect on cell proliferation. However, anti-DC1 affects the generation of effector T cells mediating specific cytolytic activity, whereas no inhibitory effect can be observed on natural killer (NK) and antibody-dependent cytotoxic cell (ADCC) activities.

Materials and Methods

Monoclonal Antibodies. Derivation of the MAb used in the present study has been previously described (6, 9, 10). The anti-DR PTF29.12 is an IgG2 antibody to a nonpolymorphic determinant of human DR molecules; BT3/4 is an IgG1 antibody directed at a polymorphic determinant of DC molecules present on the DC1 allele (6). The MAb were used in the form of purified IgG at a final concentration of 50 µg/ml unless otherwise specified.

* Supported in part by grant 81.01344.96 from the CNR PFCCN.
Cell Cultures. Peripheral blood mononuclear cells (PBMC) were obtained from donors typed for DR and DC1 as previously described (11). The responding cell population in mixed lymphocyte culture (MLC) consisted either of PBMC or purified T lymphocytes obtained by isolating lymphocytes forming rosettes with neuraminidase-treated sheep erythrocytes (E-rosetting cells) by two sequential centrifugations on Ficoll-Hypaque density gradients. T cells were freed of erythrocytes by treatment with ammonium chloride buffer. The stimulating cell population, consisting of either PBMC or E rosette-depleted cells, was irradiated with 4,500 rad using a Cesium source. Unidirectional MLC were set up by culturing responding cells either in macrowells (10⁶ cells/well) or in round-bottomed microwells (10⁵ cells/well) with equal numbers of irradiated allogeneic cells in RPMI 1640 containing 10% fetal calf serum (FCS) as previously described (11). Control samples included responding or stimulating cells cultured alone. MAb were added at the onset of the culture, unless otherwise specified, at a dose of 5 µg/well, in the case of microcultures, or at a dose of 50 µg/well, when MLC were set up in macrowells. Cell proliferation and cytotoxicity were assessed on day 7 as previously described (12). Briefly, to evaluate cell proliferation, tritiated thymidine ([³H]TdR) was added to triplicate microwell cultures 18 h before harvesting. Cytolytic assays were performed against (a) phytohemagglutinin (PHA)-induced blasts derived from the stimulator cell population, (b) K 562 cell line, and (c) antibody-coated murine L 1210 tumor cells. Varying numbers (37.5 × 10⁴ to 5 × 10⁵) of T lymphocytes were incubated in V-bottomed wells of microtiter trays with 5 × 10⁴ ⁵¹Cr-labeled target cells at a final volume of 200 µl, thus ensuring lymphocyte/target cell ratios ranging from 7.5:1 to 100:1. The microplates were centrifuged at 100 g for 7 min. Cytolysis was then assessed by counting the radioactivity of 0.1 ml supernatant for 1 min in a scintillation counter. Specific lysis was calculated according to Cerottini et al. (13). Pokeweed mitogen (PWM) and tetanus toxoid stimulation were performed as previously described (11).

Results and Discussion

Unidirectional MLC were set up, to which BT3.4 (anti DC1) MAb was added at the onset of culture. It should be noted that either the responder or the stimulating cell population was DC1 positive. As BT3.4 is specific for that allele of the DC locus, this ensured that the antibody could react with the responder or the stimulating cell population, but not with both.

As shown in Table I, in no instance did the presence of the anti-DC1 Mab inhibit T cell proliferation. Under the same experimental conditions, an anti-DR MAb

| Experiment Number | R     | S     | Antibody added | [³H]TdR cpm |
|-------------------|-------|-------|----------------|-------------|
| 1                 | DR 2w6 DC1⁺ | DR 5 DC1⁻ | None           | 57,993 ± 1,425* |
|                   |       |       | BT3.4          | 46,837 ± 684 |
|                   |       |       | PTF29.12       | 4,850 ± 720 |
| 2                 | DR 2w6 DC1⁺ | DR 4.5 DC1⁻ | None           | 52,323 ± 3,198 |
|                   |       |       | BT3.4          | 60,102 ± 1,426 |
|                   |       |       | PTF29.12       | 67,290 ± 2,492 |
| 3                 | DR 1.2 DC1⁺ | DR 5 DC1⁻ | None           | 56,098 ± 1,163 |
|                   |       |       | BT3.4          | 51,918 ± 1,023 |
|                   |       |       | PTF29.12       | 35,944 ± 2,802 |
| 4                 | DR 2w6 DC1⁺ | DR 3.7 DC1⁻ | None           | 45,933 ± 2,518 |
|                   |       |       | BT3.4          | 44,878 ± 2,518 |
| 5                 | DR 3.5 DC1⁻ | DR 1.2 DC1⁺ | None           | 57,690 ± 1,867 |
|                   |       |       | BT3.4          | 44,878 ± 2,518 |
| 6                 | DR 5 DC1⁻ | DR 2w6 DC1⁺ | None           | 45,230 ± 2,518 |
|                   |       |       | PTF29.12       | 4,635 ± 600 |

* Values are expressed as mean cpm ± SD of triplicate cultures after having subtracted background counts due to responder and stimulator cells cultured alone.
reduced [\(^{3}H\)]TdR uptake to <10% the control value. Thus, unlike anti-DR antibodies, anti-DC1 does not interfere with T cell proliferation in MLC. Only one experiment is reported for the anti-DR MAb, as it reacts against a nonpolymorphic determinant of DR molecules and hence its effect is independent of the phenotype of the cell. Effector T cells are generated during MLC that are responsible for the lysis of (a) PHA-induced blast cells bearing the stimulating alloantigens, (b) K562 erythroid tumor line (nonspecific killing or NK-like), and (c) antibody-coated target cells (ADCC activity). We have investigated whether the anti-DC1 MAb had any effect on these various cytolytic activities. As shown in Figs. 1 and 2, when the effector cells were derived from MLC in which BT3.4 MAb was added from the onset of the culture, a marked difference in terms of specific cytolytic activity (CTL) was observed, depending upon the phenotype of the donors used. In fact, when the responding cells were DC1 negative and the stimulating cells DC1 positive (Fig. 1), no difference could be observed between the specific effector T cells generated in such combination and those obtained from control cultures to which BT3.4 was not added.

On the other hand, when the reverse combination was used (responder DC1 positive, stimulator DC1 negative), those activated T cells generated were virtually devoid of CTL activity. No differences were observed in between the combinations in terms of effector cells capable of killing in ADCC- or in NK-like activity (data not shown). Furthermore, the addition of BT3.4 directly to the cytolytic test could, at this stage, affect neither the specific cytolytic activity of DC1-positive effector T cells generated in MLC nor the killing of DC1-positive target cells (data not shown).

To check whether the anti-DC1 antibody had any effect on proliferation to a soluble antigen or on B cell differentiation, PBMC from DC1-positive donors were stimulated in culture with optimal concentrations of PWM or tetanus toxoid in the presence and in the absence of the MAb. Proliferation was evaluated by [\(^{3}H\)]TdR uptake, and B cell differentiation was determined by the number of cytoplasmic Ig (cIg) -positive cells stained by a fluorescein isothiocyanate (FITC) -coupled anti-

![Graph](https://example.com/graph.png)

**Fig. 1.** Specific CTL activity of DC1-negative T cell populations activated in MLC. T cells were cultured for 7 d in allogeneic MLC, and thereafter their cytolytic activity against the PHA-activated cells bearing the stimulating alloantigens was tested. From left to right: experiments 5 and 6 of Table I. Untreated control (○); MLC treated with BT3/4 (△).
human Ig antibody and the amount of Ig secreted in the culture fluid. As shown in Table II, the presence of BT3.4 reduced neither proliferation, the number of c Ig positive cells, nor the amount of secreted Ig, whereas the anti-DR antibody abolished the response to both PWM and the soluble antigen (data not shown).

The above results show that in in vitro systems the effect of an antibody directed against a product of the DC locus is quite different from that of an antibody directed against a product of the DR locus. Thus, proliferation of T cells, or at least of most of them, is not disturbed by the anti-DC1 antibody, whereas unmasked DC molecules seem to be essential for proliferation and/or differentiation of CTL precursors in MLC. At this stage, however, it is impossible to tell whether these cells are blocked by a negative signal generated by the interaction of the antibody with membrane DC1 or because masking of the molecule prevents recognition of the allogeneic cell. Nevertheless, it is clear that DC molecules are neither receptors nor target molecules necessary for lysis of the target cells, as shown by the lack of effect of the antibody
added directly to the cytolytic test. Taken together, the above results indicate that DC molecules are not only, as previously shown (6), structurally different from DR molecules, but also that they play distinct functions on the surface of B and T lymphocytes.

Summary

The products of the DC locus have been shown to be structurally different from those of the DR locus. In this paper it is shown that, unlike anti-DR antibodies, a monoclonal antibody directed against DC1 does not affect proliferation of T cells in response to alloantigens or soluble antigens or production of Ig in a pokeweed mitogen-stimulated in vitro culture. However, the anti-DC1 inhibits the generation of effector T cells mediating specific cytolytic activity, whereas no inhibitory effect can be observed on natural killer and antibody-dependent cytotoxic cell activities.

Received for publication 26 July 1982.

References

1. Sorrentino, R., G. Corte, F. Calabi, N. Tanigaki, and R. Tosi. 1981. A three loci model for the control of the small (beta) subunit of human Ia molecules. In Expression of Differen
tiated Functions in Cancer Cells. R. Revoltella, G. Pontieri, C. Basilico, G. Rovero, R. Gallo, and J. Subak-Sharte, editors. Raven Press, New York. 169–178.

2. Tanigaki, N., R. Tosi, D. Pressman, and G. B. Ferrara. 1980. Molecular identification of human Ia antigens coded for by a gene locus closely linked to HLA-DR locus. Immunogenetics. 10:151.

3. van Rood, J. J., J. A. van Leeuwen, A. Termiitelen, and J. J. Kevning. 1976. Ia-Like determinants and their relation to MLC determinants in man. In The Role of Products of the Histocompatibility Gene Complex in Immune Response. D. H. Katz, and B. Benacerraf, editors. Academic Press, Inc., New York, p. 51–72.

4. Russo, C., V. Quaranta, F. Indiveri, M. A. Pellegrino, and S. Ferrone. 1980. Effect of polyclonal and monoclonal anti HLA-DR xenoantibodies on xenogeneic mixed lymphocyte reactions. Immunogenetics. 11:412.

5. Accolla, R. S., A. Moretta, and J.-C. Cerottini. 1981. Allogeneic mixed lymphocyte reactions in humans: pretreatment of either the stimulator or the responder cell population with monoclonal anti-Ia antibodies leads to an inhibition of cell proliferation. J. Immunol. 127:2438.
6. Corte, G., F. Calabi, G. Damiani, A. Bargellesi, R. Tosi, and R. Sorrentino. 1981. Human Ia molecules carrying DC1 determinants differ in both alpha and beta subunits from Ia molecules carrying DR determinants. *Nature (Lond.).* 292:357.

7. Shackelford, D. A., D. C. Mann, J. J. van Rood, G. B. Ferrara, and J. L. Strominger. 1981. Human B cell alloantigens DC1, MT1 and LB12 are identical to each other but distinct from the HLA-DR antigen. *Proc. Natl. Acad. Sci. U. S. A.* 78:4566.

8. Tosi, R., N. Tanigaki, D. Centis, G. B. Ferrara, and D. Pressman. 1978. Immunological dissection of human Ia molecules. *J. Exp. Med.* 148:1592.

9. Corte, G., G. Damiani, F. Calabi, M. Fabbi, and A. Bargellesi. 1981. Analysis of HLA-DR polymorphism by two-dimensional peptide mapping. *Proc. Natl. Acad. Sci. U. S. A.* 78:534.

10. Tosi, R., N. Tanigaki, R. Accolla, R. Sorrentino, and G. Corte. 1981. Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody. *Eur. J. Immunol.* 11:721.

11. Corte, G., L. Moretta, G. Damiani, M. C. Mingari, and A. Bargellesi. 1982. Human T cell subpopulations defined by a monoclonal antibody. I. A small subset is responsible for proliferation to allogeneic cells or to soluble antigens and for helper activity for B cell differentiation. *J. Immunol.* 128:16.

12. Moretta, A., G. Corte, M. C. Mingari, and L. Moretta. 1982. Human T cell subpopulations defined by a monoclonal antibody. II. Evidence for cell cooperation in the response to alloantigens and generation of cytolytic cells. *J. Immunol.* 128:20.

13. Cerottini, J.-C., H. D. Engers, H. R. MacDonald, and K. T. Brunner. 1974. Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte reactions. *J. Exp. Med.* 140:703.